Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesylate vs heparin for anticoagulation in blood purification in severe acute pancreatitis
ChiCTR2500111161Phase 4Not yet recruiting
- Sponsor
- Weifang People's Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in acute pancreatitis (AP) comparing nafamostat mesylate group with heparin group (2 arms). Primary endpoint: Average service life of the blood purification circuit or filter. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Nafabelltanheparin
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR2500111161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111161.